We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

97 hedge funds and large institutions have $464M invested in Avalo Therapeutics in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 30 increasing their positions, 20 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

654% more call options, than puts

Call options by funds: $43M | Put options by funds: $5.7M

74% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 19

50% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 20

29% more capital invested

Capital invested by funds: $361M → $464M (+$103M)

26.83% more ownership

Funds ownership: 109.66% → 136.49% (+27%)

15% more funds holding

Funds holding: 84 → 97 (+13)

Holders
97
Holders Change
+13
Holders Change %
+15.48%
% of All Funds
1.19%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
33
Increased
30
Reduced
20
Closed
19
Calls
$43M
Puts
$5.7M
Net Calls
+$37.3M
Net Calls Change
+$34.6M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$41.6M
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$33.8M
3
ACA
Avoro Capital Advisors
New York
+$22M
4
FCM
Farallon Capital Management
California
+$14.3M
5
RI
RTW Investments
New York
+$13.4M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$11.1M
2
SCM
Silverarc Capital Management
Massachusetts
-$9.52M
3
Marshall Wace
Marshall Wace
United Kingdom
-$5.92M
4
PSC
Patient Square Capital
California
-$5.67M
5
JG
Jain Global
New York
-$3.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
101
Susquehanna International Group
Pennsylvania
– -$3.3M -210,994 Closed
SC
102
SummitTX Capital
Texas
– -$3.56M -195,873 Closed
SCM
103
Superstring Capital Management
New York
– -$2.78M -153,313 Closed
SCM
104
Squadron Capital Management
Illinois
– -$2.36M -130,000 Closed
FAM
105
Fred Alger Management
New York
– -$1.45M -80,092 Closed
SCM
106
Sio Capital Management
New York
– -$1.31M -72,173 Closed
WP
107
Woodline Partners
California
– -$945K -52,041 Closed
AI
108
Atom Investors
Texas
– -$930K -51,194 Closed
Two Sigma Advisers
109
Two Sigma Advisers
New York
– -$897K -49,400 Closed
Walleye Capital
110
Walleye Capital
New York
– -$757K -41,693 Closed
IC
111
Ikarian Capital
Texas
– -$486K -31,106 Closed
TRCT
112
Tower Research Capital (TRC)
New York
– -$159K -8,737 Closed
Belvedere Trading
113
Belvedere Trading
Illinois
– -$82.2K -4,526 Closed
Acadian Asset Management
114
Acadian Asset Management
Massachusetts
– -$26K -1,471 Closed
Citigroup
115
Citigroup
New York
– -$20.8K -1,143 Closed
Group One Trading
116
Group One Trading
Illinois
– -$16 -1 Closed
1 2 3 4
5

AVTX Hedge Fund Activity: Q1 2026 in Review

97 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2026, worth a combined $464M — up 29% from $361M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new AVTX positions and 19 closed out — a net gain of 14 holders — while 30 added to existing stakes and 20 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $41.6M. The largest seller was OrbiMed, cutting an estimated $11.1M.

  • 97 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2026, up from 84 in Q4 2025.
  • Funds reported $464M of Avalo Therapeutics stock for Q1 2026, up 29% quarter-over-quarter.
  • 33 funds opened new Avalo Therapeutics positions in Q1 2026 and 19 closed out, a net change of +14 holders.
  • The largest Avalo Therapeutics buyer in Q1 2026 was Fidelity Investments, an estimated $41.6M added.
  • The largest Avalo Therapeutics seller in Q1 2026 was OrbiMed, an estimated $11.1M sold.

Based on aggregated 13F filings for Q1 2026.